CDTX241220P5000
- 0.00
- 0.000.00%
Cidara Therapeutics Newsroom
Cidara Therapeutics' CD388: Promising Influenza Prevention Drives Buy Rating
H.C. Wainwright Maintains Cidara Therapeutics(CDTX.US) With Buy Rating, Maintains Target Price $24
Cidara Therapeutics Analyst Ratings
Guggenheim Initiates Coverage On Cidara Therapeutics With Buy Rating, Announces Price Target of $33
Guggenheim Initiates Cidara Therapeutics(CDTX.US) With Buy Rating, Announces Target Price $33
Needham Maintains Cidara Therapeutics(CDTX.US) With Buy Rating, Maintains Target Price $25
H.C. Wainwright Maintains Cidara Therapeutics(CDTX.US) With Buy Rating, Maintains Target Price $24
Promising Results of CD388 Lead to Buy Rating for Cidara Therapeutics
H.C. Wainwright Maintains Cidara Therapeutics(CDTX.US) With Buy Rating, Maintains Target Price $24
HC Wainwright & Co. Reiterates Buy on Cidara Therapeutics, Maintains $24 Price Target
Cidara Therapeutics Analyst Ratings
HC Wainwright & Co. Upgrades Cidara Therapeutics to Buy, Announces $24 Price Target
Cidara Therapeutics Analyst Ratings
Needham Reiterates Buy on Cidara Therapeutics, Maintains $25 Price Target
Needham Maintains Cidara Therapeutics(CDTX.US) With Buy Rating, Maintains Target Price $25
Cidara Therapeutics Analyst Ratings
Cidara Therapeutics Analyst Ratings
Needham Reiterates Buy on Cidara Therapeutics, Maintains $25 Price Target
Buy Rating Justified by Cidara Therapeutics' Upcoming Clinical Trials and Expanding Oncology Pipeline
Needham: Maintaining the Cidara Therapeutics (CDTX.US) rating, adjusted from buy to buy rating, and the target price was adjusted from $3.00 to $25.00.